

REMARKS

In response to the Restriction Requirement (paper 11) mailed from the United States Patent and Trademark Office on April 10, 2001, Applicants elect species (g) "a method for increasing blood flow" (claims 167-174, 179-182, 185-187, 190-196, 199-200, 203-204 and 217-223), for further prosecution on the merits.

Claim 167 as amended is directed to subjects that are nonhypercholesterolemic. This amendment simply incorporates the limitation of canceled claim 169, thus, effectively making the election of species requested by the Examiner with respect to subject's condition. As a result of this amendment Applicants believe that a further election of species is unnecessary. Claims 168, 173, 174, 179-182, 185-187, 190-196, 199-200, 203-204 and 217-223 are all dependent from claim 167 and readable thereon. Applicants reserve the right to file one or more continuing applications on the non-elected and/or canceled subject matter resulting from the foregoing amendment.

Applicants believe that each of the pending claims is in condition for allowance. Applicants respectfully request that the Examiner telephone the undersigned representative in the event that the claims are not found to be in condition for allowance or that the response to the restriction requirement is incomplete.

If the Examiner has any questions and believes that a telephone conference with Applicants' representative would prove helpful in expediting the prosecution of this application, the Examiner is urged to call the undersigned at (617) 720-3500 (Extension 286).

Respectfully submitted,

Konstantinos Andrikopoulos

Konstantinos Andrikopoulos

Reg. No. P-48,915

WOLF, GREENFIELD & SACKS, P.C.

600 Atlantic Avenue

Boston, MA 02210-2211

Telephone: (617) 720-3500

Attorney Docket No. R0547/7007 (ERG/KA)

Date: August 10, 2001

xAugust 10, 2001

MARKED-UP CLAIMS

167.(Amended) A method for increasing blood flow in a tissue of a nonhypercholesterolemic subject, comprising:

administering to a nonhypercholesterolemic subject in need of such treatment a HMG-CoA reductase inhibitor in an amount effective to increase endothelial cell Nitric Oxide Synthase activity in the tissue of the subject.